Business Wire23d
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
This TNBC data was initially presented at the San Antonio Breast Cancer Symposium in 2022. LP-184's unique mechanism of action is driven by the enzymatic activation of the drug by Prostaglandin ...